Multi-level Determinants of Starting ART Late: Aim 3 (LSTART)
The availability of HIV care and treatment programs is increasing in sub-Saharan Africa. However more than half the patients who need HIV treatment are still not receiving antiretroviral therapy (ART). This can lead to early death from AIDS. Additionally, many patients start ART late after the HIV disease is very advanced. This results in high death rates soon after starting ART. The factors that contribute to late ART initiation are still unclear. This study will identify factors that help patients to enroll or prevent them from enrolling into HIV care and starting ART on time. We will examine the characteristics of all patients initiating ART at study sites. We will also look at potential risk factors among patients who initiate ART late (cases) compared to patients who initiate earlier (controls) at 6 HIV care and treatment clinics in Ethiopia. Data will be collected using 2 methods:
- Face-to-face interviews with participants using questionnaires
- Obtaining clinical data from the electronic patient-level database
Identifying factors that help patients to start or prevent them from starting ART on time will help to direct interventions, programs and policies to reduce early death.
Human Immunodeficiency Virus (HIV)
Acquired Immune Deficiency Syndrome (AIDS)
|Study Type:||Observational [Patient Registry]|
|Study Design:||Observational Model: Case Control
Time Perspective: Prospective
|Target Follow-Up Duration:||12 Months|
|Official Title:||Multi-level Determinants of Starting ART Late in Sub-Saharan Africa (LSTART Study): A Case-control Study to Identify Individual-level Risk Factors for Late ART Initiation in Ethiopia|
- Appointment adherence [ Time Frame: 12 months ] [ Designated as safety issue: No ]Abstraction data from electronic patient-level database will be assessed at enrollment (looking at all prior data), 6 months, and 12 months to assess appointment adherence.
- Frequency of clinical and CD4 monitoring [ Time Frame: 12 months ] [ Designated as safety issue: No ]Abstraction data from electronic patient-level database will be assessed at enrollment, 6 months, and 12 months will be used to assess the frequency of clinical and CD4 monitoring.
- Mortality rates at 6 months and 12 months [ Time Frame: 12 months ] [ Designated as safety issue: No ]Abstraction data from electronic patient-level database will be assessed at enrollment (looking at all prior data), 6 months, and 12 months to assess mortality rates of HIV-positive patients at 6 months and 12 months after they initiate ART.
- Rate of Loss to Follow-Up [ Time Frame: 12 months ] [ Designated as safety issue: No ]Abstraction data from electronic patient-level database will be assessed at enrollment (looking at all prior data), 6 months, and 12 months to assess rates of loss to follow-up at 6 and 12 months after patients initiate ART.
|Study Start Date:||June 2012|
|Estimated Study Completion Date:||February 2015|
|Estimated Primary Completion Date:||April 2014 (Final data collection date for primary outcome measure)|
Key Informant Interviews
Eligible patients will undergo a one hour structured interview about barriers and facilitators to early ART initiation.
The prospective cohort will include all patients initiating ART at one of the six study sites, estimated at 1,200 patients. Cases will be adults initiating ART with either: CD4 count <150 cells/µL. Controls will be adults who initiate ART with CD4≥200 . Individuals initiating ART with CD4 counts of 150-199 cells per µL and at WHO Stage I-III will be excluded from the case-control analysis in order to ensure meaningful distinction between the two groups. We will enroll 720 patients for the case control study nested in the prospective cohort, which will include 360 cases and 360 controls, who will be frequency matched by sex, month of ART initiation, and clinic.
Background: Although HIV care and treatment programs are being scaled up in sub-Saharan Africa, more than 50% of the patients in need of ART are not receiving it and there is still significant mortality from AIDS. One of the major challenges is high rates of late ART initiation (i.e., in the advanced stages of HIV disease) which results in high rates of mortality soon after initiation of ART. The individual-level factors that contribute to late ART initiation are still unclear. Objective: As the 3rd part of a 3-phase NIH-sponsored project, this study aims to identify individual-level enablers and barriers to timely enrollment into HIV care and ART initiation.
Methods: We will be recruiting all patients newly initiating ART at the study sites for descriptive analysis (approximately 1,200). As a sub-analysis, we will be utilizing a case-control approach to examine potential individual risk factors (e.g. knowledge and behaviors around HIV care and treatment, experience of stigma, and other perceived barriers and enablers to earlier HIV diagnosis, enrollment into care, and ART initiation) among 360 patients who initiated ART late (CD4 count <150 cells/µL compared to 360 patients who initiated earlier (CD4≥200) at 6 HIV care and treatment clinics in Ethiopia. For both the descriptive study and case-control study, data will be collected using 2 methods:
- Face-to-face interviews with participants using structured questionnaires
- Abstraction of clinical data from the electronic patient-level database to capture patient information at baseline, 6 and 12 months after enrollment in the study
Expected use of results: Identifying individual-level enablers and barriers of timely ART initiation will facilitate implementation of interventions, programs and policies to mitigate the problem of late ART initiation.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01997359
|Principal Investigator:||Batya Elul, PhD, MSc||ICAP-NY, Columbia University|